However, in the last three decades, survival rates have progressively improved because enhanced of screening programs with early cancer detection, advancements in surgical techniques (i.e., minimally invasive approaches), the implementation of prehabilitation and enhanced recovery after surgery pathways, neoadjuvant and/or adjuvant chemoradiation treatments in patients with locally advanced disease, treatments focused on human epidermal growth factor 2 (HER-2) protein overexpression, gene amplification, and adjuvant immunotherapy protocols in PD-L1-positive patients [58,59,60,61,62,63,64,65]. The gene discussed is ERBB2; the disease is cancer.